Coriell Life Sciences (CLS) https://www.coriell.com a provider of molecular test interpretation and reporting is offering their coronavirus analysis and reporting services to laboratories in the U.S. at no cost during the public health crisis.
“Laboratory testing is not as simple as running a sample through a machine. The results must be interpreted and developed into a clinical report that laboratories either need to design and build, or they can partner with providers like CLS. To speed our national response to stemming the spread of the COVID-19 virus, we feel we can contribute by creating a ready-made path for laboratories when ramping up access to this testing,” said Scott Megill, President, and CEO of CLS.
CLS recognizes the need to implement testing and reporting solutions immediately. With so many citizens at risk for infection and the national focus on preventing the spread of the disease, the goal is to make the process at CLS as simple and efficient as possible while healthcare organizations continue to pursue Emergency Use Authorization (EUA).